Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ORIC PHARMACEUTICALS, INC.

(ORIC)
  Report
Delayed Quote. Delayed Nasdaq - 09/17 04:00:00 pm
25.22 USD   +2.65%
09/14INSIDER SELL : Oric Pharmaceuticals
MT
09/09INSIDER SELL : Oric Pharmaceuticals
MT
09/01ORIC PHARMACEUTICALS : to Participate in Upcoming Investor Conferences
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
24.35(c) 24.96(c) 25.06(c) 24.57(c) 25.22(c) Last
188 176 115 163 147 798 175 622 1 506 128 Volume
-2.13% +2.51% +0.40% -1.96% +2.65% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -84,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -11,3x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -115 M - -
Net Debt 2022 - - -
P/E ratio 2022 -8,72x
Yield 2022 -
Capitalization 992 M 992 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 70
Free-Float 99,0%
More Financials
Company
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patientsÔÇÖ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product... 
Sector
Biotechnology & Medical Research
Calendar
09/22 | 02:55pmPresentation
More about the company
Ratings of ORIC Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about ORIC PHARMACEUTICALS, INC.
09/14INSIDER SELL : Oric Pharmaceuticals
MT
09/09INSIDER SELL : Oric Pharmaceuticals
MT
09/01ORIC PHARMACEUTICALS : to Participate in Upcoming Investor Conferences
AQ
08/18ORIC PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
08/16ORIC PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Change ..
AQ
08/16ORIC PHARMACEUTICALS : Appoints Steven L. Hoerter to its Board of Directors (For..
PU
08/16ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
GL
08/16ORIC Pharmaceuticals, Inc. Announces Board Changes
CI
08/10ORIC PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Operati..
PU
08/10ORIC PHARMACEUTICALS : Management's Discussion and Analysis of Financial Conditi..
AQ
08/10ORIC PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fina..
AQ
08/10ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operat..
GL
08/10Oric Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter En..
CI
07/12ORIC PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
07/08ORIC PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
More news
News in other languages on ORIC PHARMACEUTICALS, INC.

- No features available -

More news
Analyst Recommendations on ORIC PHARMACEUTICALS, INC.
More recommendations
Chart ORIC PHARMACEUTICALS, INC.
Duration : Period :
ORIC Pharmaceuticals, Inc. Technical Analysis Chart | ORIC | US68622P1093 | MarketScreener
Technical analysis trends ORIC PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 25,22 $
Average target price 42,71 $
Spread / Average Target 69,4%
EPS Revisions
Managers and Directors
Jacob M. Chacko President, Chief Executive Officer & Director
Dominic Piscitelli Chief Financial Officer
Pratik S. Multani Chief Medical Officer
Lori Friedman Chief Scientific Officer
Richard A. Heyman Director
Sector and Competitors
1st jan.Capi. (M$)
ORIC PHARMACEUTICALS, INC.-25.49%992
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850